加水分解ホエイペプチド高含有免疫調整栄養食による、ラット肝硬変進展の抑制効果 by Jobara, Kanta






Type Thesis or Dissertation
Textversionnone
Kyoto University
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Objective: Liver fibrosis and subsequent cirrhosis is a major cause of death worldwide, 
but few effective anti-fibrotic therapies are reported. Whey-hydrolyzed peptide (WHP), 
a major peptide component of bovine milk, exerts anti-inflammatory effects in 
experimental models. A WHP-enriched diet is widely used for immunomodulating diets 
(IMD) in clinical fields. However, the impact of WHP on liver fibrosis remains 
unknown. Here, we investigated the anti-fibrotic effects of WHP in a rat cirrhosis 
model.  
Methods: Progressive liver fibrosis was induced by repeated intraperitoneal 
administration of dimethylnitrosamine (DMN) for 3 wk. Rats were fed either a 
WHP-enriched IMD (WHP group) or a control enteral diet (Control group). The degree 
of liver fibrosis was compared between groups. Hepatocyte-protective effects were 
examined using hepatocytes isolated from rats fed a WHP diet. Reactive oxygen species 
(ROS) and glutathione (GSH) in liver tissue were investigated in the DMN cirrhosis 
model.  
Results: Macroscopic and microscopic progression of liver fibrosis was remarkably 
suppressed in the WHP group. Elevated serum levels of liver enzymes and hyaluronic 
acid, and liver tissue hydroxyproline content were significantly attenuated in the WHP 
group. Necrotic hepatocyte rates with DMN challenge, isolated from rats fed a 
WHP-enriched IMD, were significantly lower. In the DMN cirrhosis model, ROS were 
significantly lower, and GSH was significantly higher in whole liver tissue in the WHP 
group.  
Conclusion: A WHP-enriched IMD effectively prevented progression of DMN-induced 
liver fibrosis in rats via a direct hepatocyte-protective effect and an antioxidant effect 
through GSH synthesis. 
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